Can you take Rilzabrutinib with Vitamin e?
1 drug interaction and 6 additional warnings found for the following 2 drugs:
- rilzabrutinib
- vitamin e
Drug interactions
Minor drug interactions
Minor:
vitamin E rilzabrutinib
Applies to: vitamin e and rilzabrutinib
Information for this minor interaction is available on the professional version.
Food/lifestyle interactions
Major food/lifestyle interactions
Major:
rilzabrutinib Food/Lifestyle
Applies to: rilzabrutinib
Do not consume grapefruit, grapefruit juice, Seville oranges, starfruit, or supplements that contain these fruits during treatment with rilzabrutinib.
Doing so may significantly increase the blood levels of rilzabrutinib and increase the risk and/or severity of side effects such as:
- infections
- diarrhea
- nausea
- headache
Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Disease interactions
5 potential interactions Applies to: 4 conditions, including Liver Disease, Renal Dysfunction, Malabsorption Syndrome, and Biliary Obstruction.
Biliary Obstruction
Major:
vitamin e
vitamin E has a major potential interaction with Biliary Obstruction.
Vitamin E is fat soluble and many oral formulations require bile for adequate intestinal absorption. Hepatic and/or biliary dysfunction decrease the absorption of vitamin E. Water- miscible vitamin E formulations may be better absorbed from the GI tract under these conditions. Vitamin E is metabolized by the liver and primarily excreted in bile and feces. Hepatic and/or biliary impairment can alter the metabolic and therapeutic activity of vitamin E.
Liver Disease
Major:
vitamin e
vitamin E has a major potential interaction with Liver Disease.
Vitamin E is fat soluble and many oral formulations require bile for adequate intestinal absorption. Hepatic and/or biliary dysfunction decrease the absorption of vitamin E. Water- miscible vitamin E formulations may be better absorbed from the GI tract under these conditions. Vitamin E is metabolized by the liver and primarily excreted in bile and feces. Hepatic and/or biliary impairment can alter the metabolic and therapeutic activity of vitamin E.
Moderate:
rilzabrutinib
Rilzabrutinib has a moderate potential interaction with Liver Disease.
Rilzabrutinib is not recommended for use in patients with moderate or severe hepatic dysfunction (Child-Pugh B or C). Cmax and AUC increased by approximately 4.5-fold in patients with moderate hepatic dysfunction. Patients with severe hepatic dysfunction were not studied.
Malabsorption Syndrome
Minor:
vitamin e
vitamin E has a minor potential interaction with Malabsorption Syndrome.
Vitamin E is readily absorbed from the intestinal tract in the presence of bile. Prolonged fat malabsorption (cystic fibrosis, hepatic cirrhosis, sprue) or malabsorption syndromes (celiac disease, GI resection) can decrease the absorption of many oral formulations of vitamin E. A water- miscible formulation of vitamin E may be better absorbed in these conditions.
Renal Dysfunction
Moderate:
rilzabrutinib
Rilzabrutinib has a moderate potential interaction with Renal Dysfunction.
Rilzabrutinib is not recommended for use in patients with severe renal dysfunction (CrCl less than 46 mL/min). Patients with severe renal dysfunction were not studied.
Report options
More resources
rilzabrutinib
A total of 576 drugs are known to interact with rilzabrutinib.
- Rilzabrutinib is in the drug class selective immunosuppressants.
- Rilzabrutinib is used to treat Immune Thrombocytopenia.
vitamin e
A total of 273 drugs are known to interact with vitamin e.
- Vitamin e is in the drug class vitamins.
- Vitamin e is used to treat the following conditions:
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.